Page 13 - Reference Health News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The top choice among democrats and then Bernie Sanders and mayor Pete Buttigieg and then medicare and Elizabeth Warren rounding out the top five. Cnn political director David Challen is in washington, d. C. For us. And david, so hes jumping in and jumping in thursday. This is the most diverse political field in modern president ial history so what does joe bidens lane look like and how does he maintain that stop spot. I dont think we have to say modern president ial history, the most diverse field in history period. Listen, joe biden has to do a few things. One, the big question hanging around...

First debate in miami. She saw a spikeup in the polls but over the course in the last several weeks shes sort of plateaued to that about 12 area. So the question for Kamala Harris was would you be Going Forward with that similar strategy of drawing those contrasts with not only joe biden but others up in the stage and Kamala Harris was very specific telling us reporters here this week that she believes its important for not only democratic voters but for america to continue to draw those contrasts and especially over ones record saying that it is important to understand the totality of individ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly ...

Labcorp acquires certain operations of Opko Health subsidiary BioReference Health. The assets Labcorp is acquiring generate about $100 million in annual revenue, with the transaction valued at $237.5 million.

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from the fourth quarter and subsequent weeks included the following: ModeX advanced its antiviral and immune-oncology product pipeline. ModeX advanced its pipeline of antiviral and immune-oncology programs utilizing its next-generation multispecific